echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Renfu Medicine: Mifepristone tablets passed the consistency evaluation of generic drugs

    Renfu Medicine: Mifepristone tablets passed the consistency evaluation of generic drugs

    • Last Update: 2021-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On March 25, Renfu Pharmaceutical announced that recently, Hubei Gedian Renfu Pharmaceutical Co.
    , Ltd.
    , a subsidiary of the company, received the "Drug Supplementary Application Approval Notice" from the State Food and Drug Administration on mifepristone tablets (notice Book number: 2020B05143), the drug passed the generic drug quality and efficacy consistency evaluation.

    Mifepristone tablets are currently widely used pregnancy termination drugs.
    This approval adds a scope of applicable population for termination of pregnancy within 8-16 weeks (50-112 days).
    Jiulong Renfu submitted an application for consistency evaluation to the State Food and Drug Administration in 2019 and was accepted, with a cumulative R&D investment of approximately RMB 16 million.
    According to the website of the State Drug Administration, a total of 7 domestic companies hold production approvals for mifepristone tablets.
    It is specially reminded that the board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint responsibility for the authenticity, accuracy and completeness of the contents.
    According to the statistics of Meinnet.
    com, the sales of the full dosage form of mifepristone in my country's city, county and township three terminal public hospitals in 2019 is about 240 million yuan.
    The main manufacturers include Hubei Gedian Renfu Pharmaceutical Co.
    , Ltd.
    Company (including Jiulong Renfu), China Resources Zizhu Pharmaceutical Co.
    , Ltd.
    , Zhejiang Xianju Pharmaceutical Co.
    , Ltd.
    , etc.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.